Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients 18-65 years of age
chronic hepatitis C , genotype 1
serologic evidence of CHC infection by an antibody test
chronic liver disease, consistent with CHC infection on a liver biopsy obtained within the past 18 months
compensated liver disease
use of 2 forms of contraception during the study in both men and women
You may not be if
previous interferon or ribavirin therapy
systemic antiviral therapy less than 24 weeks before first dose of study drug or expected need for this treatment any time during the study
medical condition associated with chronic liver disease (eg, hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposure)
decompensated liver disease
women who are pregnant or breastfeeding
Clareo Health | Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
